ABSTRACT
A case who revealed the longest duration of viral shedding (67 days) in current reports, presented complicated characteristic on the relapse of COVID-19 due to the inconsistent performance of chest radiography and SARS-CoV-2-RNA detection after discharge. Lopinavir-interferon α2b boosted ribavirin following with lopinavir boosted budesonide might be a potent treatment for viral clearance.
Subject(s)
COVID-19/virology , SARS-CoV-2/physiology , Aftercare , COVID-19/diagnostic imaging , COVID-19/physiopathology , Female , Hospitalization , Humans , Lopinavir/therapeutic use , Middle Aged , Patient Discharge , RNA, Viral/genetics , RNA, Viral/isolation & purification , Recurrence , Ribavirin/therapeutic use , SARS-CoV-2/genetics , Thorax/diagnostic imaging , Virus Shedding/drug effects , COVID-19 Drug TreatmentABSTRACT
The evidence of long-term clinical dynamic on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA re-positive case are less. We performed a 108 days follow-up on dynamic clinical presentations in a case, who hospitalized three times due to the positive recurrence of SARS-CoV-2 RNA after discharge, to understand the prognosis of the 2019-Coronavirus disease (COVID-19). In this case, positive SARS-CoV-2 recurred even after apparent recovery (normal CT imaging, no clinical symptoms, negative SARS-CoV-2 on stool sample and negative serum IgM test) from COVID-19, viral shedding duration lasted for 65 days, the time from symptom onset to disappearance was up to 95 days. Erythrocyte-associated indicators, liver function and serum lipid metabolism presented abnormal throughout during the observation period. Awareness of atypical presentations such as this one is important to prompt the improvement of the management of COVID-19.